Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
---|---|---|---|---|---|
23.05. | GRI Bio erweitert Kapazität für At-the-Market-Angebot | 2 | Investing.com Deutsch | ||
23.05. | GRI Bio, Inc. - 8-K, Current Report | 1 | SEC Filings | ||
22.05. | GRI Bio reports progress in pulmonary fibrosis treatment | 1 | Investing.com | ||
22.05. | GRI Bio verzeichnet Fortschritte bei Behandlung von Lungenfibrose | 2 | Investing.com Deutsch | ||
GRI BIO Aktie jetzt für 0€ handeln | |||||
22.05. | GRI Bio, Inc.: GRI Bio Presents Positive Pre-Clinical Data Demonstrating GRI-0621 Resolves Inflammation and Fibrosis in Bleomycin-Induced Fibrosis and Reiterates Promising Preliminary Phase 2a Clinical Results | 2 | GlobeNewswire (USA) | ||
21.05. | GRI Bio, Inc.: GRI Bio to Participate in the Virtual Investor Closing Bell Series | 1 | GlobeNewswire (USA) | ||
16.05. | GRI Bio, Inc.: GRI Bio to Present at A.G.P.'s Annual Healthcare Company Showcase | 5 | GlobeNewswire (USA) | ||
15.05. | GRI Bio reports Q1 results | 2 | Seeking Alpha | ||
15.05. | GRI Bio reports positive early trial data for IPF treatment | 3 | Investing.com | ||
15.05. | GRI Bio, Inc. - 10-Q, Quarterly Report | - | SEC Filings | ||
15.05. | GRI Bio, Inc. - 8-K, Current Report | 1 | SEC Filings | ||
15.05. | GRI Bio, Inc.: GRI Bio Reports First Quarter 2025 Financial Results and Confirms GRI-0621 Phase 2a IPF Trial on Track for 6-Week Interim Data in Q2 2025 and Topline Data in Q3 2025 | 132 | GlobeNewswire (Europe) | Positive interim 2-week safety and biomarker results from its ongoing Phase 2a study evaluating GRI-0621 for the treatment of Idiopathic Pulmonary Fibrosis ("IPF") Continued momentum with completed... ► Artikel lesen | |
08.05. | GRI Bio reports positive interim biomarker data in IPF study | 1 | Investing.com | ||
08.05. | GRI Bio meldet positive Zwischenergebnisse bei Biomarkern in IPF-Studie | - | Investing.com Deutsch | ||
08.05. | GRI Bio, Inc.: GRI Bio's Interim Biomarker Data Demonstrate Positive Trend Towards Anti-Fibrotic Effect of GRI-0621 in First Twelve Patients of Ongoing Phase 2a Study in Idiopathic Pulmonary Fibrosis ("IPF") | 108 | GlobeNewswire (Europe) | The Independent Data Monitoring Committee (IDMC) has recommended to continue the study as planned as there are no safety concerns seen in the data reviewed Continued momentum with completed patient... ► Artikel lesen | |
07.05. | GRI Bio, Inc.: GRI Bio Continues to Drive Enrollment in Ongoing Phase 2a Study of GRI-0621 in Idiopathic Pulmonary Fibrosis ("IPF") | 145 | GlobeNewswire (Europe) | Enrollment completed for the 6-week interim analysis with 24 of the 36 planned patients now enrolled Company on track to report interim biomarker data from the first 12 patients imminently Completion... ► Artikel lesen | |
05.05. | GRI Bio, Inc. - 8-K, Current Report | 1 | SEC Filings | ||
14.04. | H.C. Wainwright maintains Buy on GRI Bio stock, $10 target | 2 | Investing.com | ||
02.04. | GRI Bio, Inc.: GRI Bio Announces Closing of $5.0 Million Public Offering | 1 | GlobeNewswire (USA) | ||
02.04. | GRI Bio, Inc. - 8-K, Current Report | 2 | SEC Filings |
Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
---|---|---|---|---|---|
BIONTECH | 103,50 | +4,65 % | Onkologie: Milliarden-Deal für BioNTech | Die Aktie des Biotechnologie-Unternehmens springt am Montagmittag zweistellig an. Auslöser ist eine Partnerschaft mit Bristol Myers Squibb. Der Deal zielt auf einen Hoffnungsträger aus der Onkologie-Pipeline... ► Artikel lesen | |
EVOTEC | 7,048 | +2,95 % | Apple, Borussia Dortmund, Evotec, K+S, Mercedes-Benz, Renk - 4investors Aktien Top-News | Wo ist am Aktienmarkt etwas los, welche Themen interessieren Anleger derzeit besonders? Vor allem für Trader ist es wichtig zu wissen, wo "die Musik spielt" und welche Themen an der Börse aktuell besonders... ► Artikel lesen | |
CUREVAC | 4,164 | +2,87 % | CureVac mit BRANDNEUER Prognose: Könnte die Aktie JETZT komplett drehen - Experten empfehlen sofort zu handeln!!! | ||
AMGEN | 254,45 | +0,95 % | Amgen Says Imdelltra Cut Risk Of Death By 40% In Small Cell Lung Cancer Patients | THOUSAND OAKS (dpa-AFX) - Amgen Inc. (AMGN) Monday announced positive interim results from the Phase 3 DeLLphi-304 study showing Imdelltra reduced the risk of death by 40% and significantly... ► Artikel lesen | |
PALATIN TECHNOLOGIES | 0,077 | 0,00 % | Palatin Technologies Q1 Net Loss Narrows On Lower Expenses | WASHINGTON (dpa-AFX) - Palatin Technologies, Inc. (PTNT.PK), a biopharmaceutical company, on Wednesday reported narrower net loss in its first quarter with sharply lower operating expenses.Palatin... ► Artikel lesen | |
BIOXXMED | 0,410 | 0,00 % | XETR DELETION OF INSTRUMENTS FROM XETRA - 31.03.2025 | The following instruments on Xetra do have their last trading day on 31.03.2025.Die folgenden Instrumente auf Xetra haben ihren letzten Handelstag am 31.03.2025.ISIN NameDE000A4BGGE4 bioXXmed AG ► Artikel lesen | |
VIVOSIM LABS | 1,570 | -100,00 % | VivoSim Labs, Inc.: VivoSim Announces Emergence from Stealth Mode To Provide Technologies for FDA Turn Away from Animal Models, $10B+ Market | SAN DIEGO, April 24, 2025 (GLOBE NEWSWIRE) -- VivoSim Labs, Inc. (Nasdaq: VIVS) (the "Company") announced that it has emerged from stealth mode to dramatically impact drug discovery and development.... ► Artikel lesen | |
OCUGEN | 0,736 | +1,27 % | Ocugen Announces Rare Pediatric Disease Designation Granted for OCU410ST-Modifier Gene Therapy for the Treatment of Stargardt Disease | MALVERN, Pa., May 27, 2025 (GLOBE NEWSWIRE) -- Ocugen, Inc. (Ocugen or the Company) (NASDAQ: OCGN), a pioneering biotechnology leader in gene therapies for blindness diseases, today announced that... ► Artikel lesen | |
SIRONA BIOCHEM | 0,037 | -100,00 % | Sirona Biochem gibt Finanzierung mittels Wandelschuldverschreibung bekannt | Vancouver, British Columbia, 22. April 2025 / IRW-Press / Sirona Biochem Corp. (TSX-V: SBM) (FWB: ZSB) (OTC: SRBCF) ("Sirona" oder das "Unternehmen") gibt eine nicht vermittelte Privatplatzierung... ► Artikel lesen | |
BIO-GATE | 1,040 | 0,00 % | Bio-Gate: Zusätzlicher Wachstumstreiber bei Wundversorgung | Nach Darstellung der Analysten Matthias Greiffenberger und Cosmin Filker von GBC besitzt die Bio-Gate AG für ein Spray im Bereich der Wundversorgung zusätzliche Vermarktungsoptionen mit großem Potenzial.... ► Artikel lesen | |
DEFENCE THERAPEUTICS | 0,508 | +2,63 % | Defence Therapeutics Inc.: Defence Therapeutics Opens U.S. Laboratory in Boston-Cambridge Biotech Hub | Montreal, Quebec--(Newsfile Corp. - June 2, 2025) - Defence Therapeutics Inc. (CSE: DTC) (OTCQB: DTCFF) (FSE: DTC) ("Defence" or the "Company"), a leading biotechnology company specializing in advanced... ► Artikel lesen | |
NUREXONE BIOLOGIC | 0,458 | +3,39 % | Im Visier der Instis: NurExone mit AbbVie auf einer Bühne! | ||
VAXART | 0,413 | +5,67 % | Vaxart, Inc.: Vaxart Announces Adjournment of Annual Meeting of Stockholders | ||
IBIO | 0,828 | 0,00 % | iBio, Inc.: iBio Reports Fiscal Third Quarter 2025 Financial Results | SAN DIEGO, May 02, 2025 (GLOBE NEWSWIRE) -- iBio, Inc. (Nasdaq:IBIO), today reported financial results for the third quarter ended March 31, 2025, and provided a corporate update on its progress.... ► Artikel lesen | |
BURCON NUTRASCIENCE | 0,065 | +4,85 % | Burcon NutraScience Corporation: Burcon to Participate in 2025 Canadian Climate Investor Conference | Vancouver, British Columbia--(Newsfile Corp. - May 28, 2025) - Burcon NutraScience Corporation (TSX: BU) (OTCQB: BRCNF) ("Burcon" or the "Company"), a global technology leader in the development of... ► Artikel lesen |